DUPIXENT reduced or eliminated OCS use and improved more than one measure of asthma control3,5
DUPIXENT reduced or eliminated steroids while simultaneously improving asthma control3,5
No biomarker requirement, ITT population: Reduced or eliminated OCS dose and reduced severe exacerbation rates and improved lung function (secondary endpoints) at Week 243,5,d-f
- Effects on lung function and on oral steroid and exacerbation reduction were similar irrespective of baseline blood eosinophil levels. Subjects with baseline blood eosinophil levels up to 1500 cells/μL were included3
- 70% significant reduction in OCS dose (median 100%)
from baseline at Week 24 with DUPIXENT 300 mg Q2W + SOC (n=103)
(95% CI: 60%, 80%) vs 42% (median 50%) with placebo + SOC (n=107) (primary endpoint)3
a At Week 24 with DUPIXENT 300 mg Q2W + SOC (n=103) vs 68% with placebo + SOC (n=107) in VENTURE.5
b At Week 24 with DUPIXENT 300 mg Q2W + SOC (n=103) vs placebo + SOC (n=107) (0.65 vs 1.60; rate ratio: 0.41 [95% CI: 0.26, 0.63]) in VENTURE.3
c At Week 24 with DUPIXENT 300 mg Q2W + SOC (n=103) vs 10 mL with placebo + SOC (n=107) (LSM difference: 220 mL [95% CI: 90, 340 mL]) in VENTURE.5
d ITT population was unrestricted by minimum baseline eosinophils or other type 2 biomarkers (eg, FeNO or IgE).5
e The baseline mean OCS dose was 12 mg in the placebo group and 11 mg in the group receiving DUPIXENT.3
f Asthma exacerbation was defined as a temporary increase in OCS dose for at least 3 days.3
No biomarker testing required for 99% of OCS-dependent asthma patients who are commercially insured7
FeNO, fractional exhaled nitric oxide; GINA, Global Initiative for Asthma; ITT, intention-to-treat; LSM, least squares mean; OCS, oral corticosteroid; Q2W, once every 2 weeks; SOC, standard of care.
of patients from VENTURE eliminated their OCS dose for up to ~3
years
with DUPIXENT6
A gradual increase in the number of patients eliminating their OCS dose was observed from 53.3% at Week 0 (n=48) to 59.6% at Week 48 (n=34) to 78.9% at Week 96 (n=15) in the DUPIXENT/DUPIXENT group (TRAVERSE OLE study, secondary endpoint)6,g
Results are descriptive. Definitive conclusions cannot be made.
Data were not multiplicity controlled and there are limitations associated with open-label study design, including lack of comparator arm,
decreasing sample size, and potential continued involvement of responders and attrition of non-responders.
gOCS reduction was at investigators’ discretion.6
No biomarker testing required for 99% of OCS-dependent asthma patients who are commercially insured7
OCS, oral corticosteroid; OLE, open-label extension.